c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia

摘要: Cervical carcinoma develops from preneoplasia by a multistep process. Although most low-grade dysplastic lesions will regress without intervention and even high-grade changes exhibit substantial rate of regression, small percentage dysplasia progress over time. Thus, indicators are needed to estimate the biological risk help avoid overtreatment in women who desire preserve fertility. In addition classical biomarkers, PCR-ELISA-determined HPV genotype immunohistochemically assessed p16INK4a Ki-67 expression, cells with integrated copy number gain TERC c-myc were quantified panel 104 benign, intraepithelial neoplastic (CIN I, II, III) cancerous using fluorescence situ hybridization. Optimal cut-off values calculated; Kaplan-Meier curves Cox proportional hazard regression model used evaluate prognostic signatures. The assay reliably identified integration, as determined comparisons established biomarkers. All biomarker levels increased progression disease. However, only independently prognosticated low probability regression. Our results suggest that plays key role process transformation might thus be exploited for treatment follow-up decision-making cervical dysplasia.